63149-24-6Relevant articles and documents
Protein triggered fluorescence switching of near-infrared emitting nanoparticles for contrast-enhanced imaging
Jetty, Ragini,Bandera, Yuriy P.,Daniele, Michael A.,Hanor, David,Hung, Hsin-I.,Ramshesh, Venkat,Duperreault, Megan F.,Nieminen, Anna-Liisa,Lemasters, John J.,Foulger, Stephen H.
, p. 4542 - 4554 (2013)
Sub-100 nm colloidal particles which are surface-functionalized with multiple environmentally-sensitive moieties have the potential to combine imaging, early detection, and the treatment of cancer with a single type of long-circulating nanodevice . Deep tissue imaging is achievable through the development of particles which are surface-modified with fluorophores that operate in the near-infrared (NIR) spectrum and where the fluorophore's signal can be maximized by turning-on the fluorescence only in the targeted tissue. We present a general approach for the synthesis of NIR emitting nanoparticles that exhibit a protein triggered activation/deactivation of the emission. Dispersing the particles into an aqueous solution, such as phosphate buffered saline (PBS), resulted in an aggregation of the hydrophobic fluorophores and a cessation of emission. The emission can be reinstated, or activated, by the conversion of the surface-attached fluorophores from an aggregate to a monomeric species with the addition of an albumin. This activated probe can be deactivated and returned to a quenched state by a simple tryptic digestion of the albumin. The methodology for emission switching offers a path to maximize the signal from the typically weak quantum yield inherent in NIR fluorophores.
Preparation and characterization of phospholipid-conjugated indocyanine green as a near-infrared probe
Suganami, Akiko,Toyota, Taro,Okazaki, Shigetoshi,Saito, Kengo,Miyamoto, Katsuhiko,Akutsu, Yasunori,Kawahira, Hiroshi,Aoki, Akira,Muraki, Yutaka,Madono, Tomoyuki,Hayashi, Hideki,Matsubara, Hisahiro,Omatsu, Takashige,Shirasawa, Hiroshi,Tamura, Yutaka
, p. 7481 - 7485 (2012)
We have rationally designed and synthesized a novel near-infrared (NIR) photoactivating probe, designated by iDOPE, in which an indocyanine green (ICG) fluorophore is covalently conjugated with a phospholipid moiety, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), to incorporate into liposome bilayers. NIR irradiation showed that iDOPE retained the optical and fluorescence properties of ICG and demonstrated photoactivator characteristics: fluorescence emission at around 820 nm in a solvent, singlet oxygen production, and concentration-dependent heat generation. Additionally, iDOPE was incorporated into liposome bilayers and maintained stable liposomally formulated iDOPE (LP-iDOPE) over 1 week under physiological conditions. We also observed the tumor-specific biodistribution of LP-iDOPE of in vivo xenografts. These findings suggest that LP-iDOPE might be a promising tool for NIR optical imaging, photodynamic therapy, and photothermal therapy.
Cyanine Nanocage Activated by Near-IR Light for the Targeted Delivery of Cyclosporine A to Traumatic Brain Injury Sites
Black, Caroline E.,Zhou, Eugene,Deangelo, Caitlin,Asante, Isaac,Yang, Rong,Petasis, Nicos A.,Louie, Stan G.,Humayun, Mark
, p. 4499 - 4509 (2021/01/01)
More than 2.8 million annually in the United States are afflicted with some form of traumatic brain injury (TBI), where 75% of victims have a mild form of TBI (MTBI). TBI risk is higher for individuals engaging in physical activities or involved in accidents. Although MTBI may not be initially life-threatening, a large number of these victims can develop cognitive and physical dysfunctions. These late clinical sequelae have been attributed to the development of secondary injuries that can occur minutes to days after the initial impact. To minimize brain damage from TBI, it is critical to diagnose and treat patients within the first or "golden" hour after TBI. Although it would be very helpful to quickly determine the TBI locations in the brain and direct the treatment selectively to the affected sites, this remains a challenge. Herein, we disclose our novel strategy to target cyclosporine A (CsA) into TBI sites, without the need to locate the exact location of the TBI lesion. Our approach is based on TBI treatment with a cyanine dye nanocage attached to CsA, a known therapeutic agent for TBI that is associated with unacceptable toxicities. In its caged form, CsA remains inactive, while after near-IR light photoactivation, the resulting fragmentation of the cyanine nanocage leads to the selective release of CsA at the TBI sites.
Preparation method and application of heptamethine benzo indole cyanine dye
-
Paragraph 0170-0174, (2020/09/23)
The invention discloses a preparation method and application of a heptamethine benzo indole cyanine dye, and belongs to the field of polymethine indole cyanine dyes and preparation thereof. The methodcomprises the following steps: 1) carrying out a heating reaction on raw materials containing a 2,3,3-trimethyl-4,5-benzoindole derivative and a nucleophilic substituted compound under a vacuum condition to obtain an organic ammonium salt; and 2) carrying out a heating reaction on a solution containing the organic ammonium salt obtained in the step 1) and a cycloalkene derivative under a closed condition, wherein the structural formula of the heptamethine benzo indole cyanine dye is represented by a formula (I). According to the invention, the dye has near-infrared light absorption and fluorescence development performances and can be used as a probe auxiliary agent; and the method has the advantages of short synthesis route, environment-friendly solvent, simple process, avoidance of noblemetal catalysis, high yield, high product purity and the like, is high in applicability, and can be used for synthesizing products of various structure types.
